ATAI
ATAI Life Sciences N.V.
Company Overview
| Mkt Cap | $1.59B | Price | $4.29 |
| Volume | 3.01M | Change | -2.94% |
| P/E Ratio | -10.7 | Open | $4.45 |
| Revenue | $308.0K | Prev Close | $4.42 |
| Net Income | $-149.3M | 52W Range | $1.15 - $6.75 |
| Div Yield | N/A | Target | $12.13 |
| Overall | 42 | Value | 40 |
| Quality | 34 | Technical | 54 |
No chart data available
About ATAI Life Sciences N.V.
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, and other mental health disorders. The company's product candidates include COMP360, BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, a transmucosal film in Phase 2 clinical study; and ELE-101, a serotonergic psychedelic for the treatment of treatment resistant depression. It also EMP-01, an oral formulation of an R-MDMA that Is in phase 2 clinical study; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, the company offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, for the treatment of generalize anxiety disorder. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ATAI | $4.29 | -2.9% | 3.01M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |